NCT07885683
MagSense® Human Epidermal Growth Factor Receptor 2 (HER2) Imaging Agent (MSH2IA)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Recruitment opened
- Study sites: 0 to 1
- Collaborators shortened, about 6 words
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Phase 1b: Level of Fe in blood
Timeframe: 24 hours post injection
Phase 2 (Imaging Schedule): Dose and Imaging schedule for MSH2IA
Timeframe: 24 hours post injection
Phase 2 (Diagnostic Performance): Diagnostic performance comparison between MSH2IA and SOC
Timeframe: 24 hours post injection
Secondary (1)
Safety and Tolerability of MSH2IA Across All Phases
Arms and interventions
Phase 1b - MSH2IA PharmacokineticsExperimental
Participants enrolled in Phase 1b will receive MSH2IA to evaluate its pharmacokinetic (PK) profile.
Phase 2 - MSH2IA Dose and Diagnostic PerformanceExperimental
Participants enrolled in Phase 2 will receive MSH2IA via subareolar or peritumoral injection to confirm the lowest effective dose, evaluate image timing, and assess the diagnostic performance of a selected dose of MSH2IA.
Combination products: The MagSense® HER2 Imaging Agent (MSH2IA)
Sites
1 site in 1 country
- Regis Clinical Research LLCMiami, Florida, United States